GE HealthCare Technologies Inc. · NASDAQ (us_market)
Healthcare · Medical Devices · United States
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-02-13$93.48 RISE2025-04-08$58.75 PEAK2025-07-02$76.12 139d | -37.2% 54d | 2025-04-07 $60.99 | 2025-07-02 $76.12 | 66Deep Value | 59Deep Value | +29.6% 85d | +24.8% Held 86d |
DROP2024-09-30$93.85 RISE2024-12-18$77.09 PEAK2025-02-13$93.48 136d | -17.9% 79d | Missed | Missed | — | — | +21.3% 57d | Missed |
DROP2024-03-08$93.87 RISE2024-06-11$74.74 PEAK2024-09-04$87.55 180d | -20.4% 95d | Missed | Missed | — | — | +17.1% 85d | Missed |
DROP2023-07-21$82.63 RISE2023-10-27$63.10 PEAK2023-12-26$78.14 158d | -23.6% 98d | Missed | Missed | — | — | +23.8% 60d | Missed |
DROP2023-06-06$82.93 RISE2023-09-21$63.89 PEAK2023-12-14$75.92 191d | -23.0% 107d | Missed | Missed | — | — | +18.8% 84d | Missed |
GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best medical technology stocks to buy right now. On May 21, UBS upgraded GE HealthCare Technologies Inc. (NASDAQ:GEHC) to Neutral from Sell and lowered its price target to $69 from $75. The firm noted that GE HealthCare’s stock valuation fell by about 30% and that this […]
These two companies are stalwarts in some of the economy's hottest industrial market segments.
GEHC teams with UW Medicine Radiology to advance CT and molecular imaging, aiming to automate workflows and speed next-gen imaging to clinics.
GEHC teams with UW Medicine Radiology to advance CT and molecular imaging, aiming to automate workflows and speed next-gen imaging to clinics.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
GE HealthCare Technologies (NasdaqGS:GEHC) has introduced new AI-driven medical imaging and workflow tools, including the iRT workflow for radiation therapy. The company has showcased updated MR systems such as SIGNA One and SIGNA Bolt, along with the helium-independent SIGNA Sprint platform. These launches were presented at leading medical conferences ESTRO 2026 and ISMRM 2026, highlighting a focus on clinical efficiency, research collaboration and sustainability in imaging. For investors...
GE HealthCare Technologies (NasdaqGS:GEHC) has introduced new AI-driven medical imaging and workflow tools, including the iRT workflow for radiation therapy. The company has showcased updated MR systems such as SIGNA One and SIGNA Bolt, along with the helium-independent SIGNA Sprint platform. These launches were presented at leading medical conferences ESTRO 2026 and ISMRM 2026, highlighting a focus on clinical efficiency, research collaboration and sustainability in imaging. For investors...
The Moat Index outperformed through February before a sharp MarchâMay selloff erased its lead. Read more here.
Etsy upgraded, ZoomInfo downgraded: Wall Street's top analyst calls
UBS analyst Graham Doyle upgrades GE HealthCare Techs (NASDAQ:GEHC) from Sell to Neutral and lowers the price target from $75 to $69.
Pre-Market Stock Futures: Futures are trading lower after a strong mid-week rally that saw all major indices close 1% or higher, following three consecutive ominous days. However, Walmart issued worse-than-expected guidance, and yields and oil are trading higher as we approach the long holiday weekend. Investors waited all day for the close in anticipation of ... Here Are Thursday’s Top Wall Street Analyst Research Calls: DraftKings, ETSY, GE Healthcare, Golar LNG, Mastec, Medtronic, Mobileye Gl
Pre-Market Stock Futures: Futures are trading lower after a strong mid-week rally that saw all major indices close 1% or higher, following three consecutive ominous days. However, Walmart issued worse-than-expected guidance, and yields and oil are trading higher as we approach the long holiday weekend. Investors waited all day for the close in anticipation of ... Here Are Thursday’s Top Wall Street Analyst Research Calls: DraftKings, ETSY, GE Healthcare, Golar LNG, Mastec, Medtronic, Mobileye Gl
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top S&P500 gainers and losers driving the post-market movements.
Cigna downgraded, Humana upgraded: Wall Street's top analyst calls
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
GE HealthCare Technologies (NASDAQ:GEHC) executives said the company remains confident in its long-term growth prospects despite a disappointing first quarter that led to a reduction in full-year guidance, citing inflationary cost pressures as the primary near-term challenge. Speaking at a Bank of
GE HealthCare Technologies (NASDAQ:GEHC) executives said the company remains confident in its long-term growth prospects despite a disappointing first quarter that led to a reduction in full-year guidance, citing inflationary cost pressures as the primary near-term challenge. Speaking at a Bank of
Wondering whether GE HealthCare Technologies stock at around US$60.76 is starting to look interesting on value, or if the risks still outweigh the potential upside. The share price has been under pressure recently, with the stock down 4.3% over the last week, 17.3% over the past month, 26.6% year to date and 16.8% over the last year. This naturally raises questions about how the current price lines up against underlying fundamentals. Recent coverage has centered on how the company is...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| GEHC | +2.15% | -22.23% | -23.99% | -11.62% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -0.82% | -16.52% | -20.55% | -24.31% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| CapResearch | fundamental | 21.11M | $1.50B | 0.23% | Trimmed-16.8% | 2026-03-31 |
| StateStreet | passive | 20.54M | $1.46B | 0.05% | Added+2.4% | 2026-03-31 |
| FidelityFMR | fundamental | 2.78M | $197.53M | 0.01% | Trimmed-17.2% | 2026-03-31 |
| DEShaw | quant | 470.4K | $33.48M | 0.02% | Trimmed-64.0% | 2026-03-31 |
| RenTech | quant | 254.1K | $18.09M | 0.03% | New | 2026-03-31 |
| Citadel | multi-strat | 125.1K | $8.90M | 0.01% | Added+66.5% | 2026-03-31 |
| Wellington | fundamental | 102.1K | $7.27M | 0.00% | Added+1.5% | 2026-03-31 |
| Bridgewater | macro | 71.8K | $5.11M | 0.02% | Added+395.9% | 2026-03-31 |
| TRowePrice | fundamental | 654.4K | $46.58K | 0.01% | Trimmed-63.0% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-26 | Lobo Kevin | Director | P Open-market purchase | 10,000 | $64.18 | +$641.8K |
| 2026-05-19 | Bankes Jeannette | CEO, Patient Care Solutions | F Tax withholding | 5,535 | $62.67 | −$346.9K |
| 2026-05-19 | Rackliffe Philip | CEO, AIS | A Grant / award | 16,458 | — | +$0 |
| 2026-05-13 | Hochman Rodney F | Director | P Open-market purchase | 1,618 | $62.03 | +$100.4K |
| 2026-05-11 | Stromberg William J | Director | A Grant / award | 3,586 | — | +$0 |
| 2026-05-11 | Madden Anne T | Director | A Grant / award | 2,282 | — | +$0 |
| 2026-05-11 | Madden Anne T | Director | A Grant / award | 3,586 | — | +$0 |
| 2026-05-11 | Lobo Kevin | Director | A Grant / award | 3,586 | — | +$0 |
| 2026-05-11 | LESJAK CATHERINE A | Director | A Grant / award | 3,586 | — | +$0 |
| 2026-05-11 | Hochman Rodney F | Director | A Grant / award | 2,689 | — | +$0 |
| 2026-05-11 | Hochman Rodney F | Director | A Grant / award | 3,586 | — | +$0 |
| 2026-05-11 | CULP H LAWRENCE JR | Director | A Grant / award | 4,157 | — | +$0 |
| 2026-05-11 | CULP H LAWRENCE JR | Director | A Grant / award | 3,586 | — | +$0 |
| 2026-05-11 | Yang Watkin Phoebe L. | Director | P Open-market purchase | 1,000 | $63.01 | +$63.0K |
| 2026-05-11 | Yang Watkin Phoebe L. | Director | A Grant / award | 3,586 | — | +$0 |
| 2026-05-07 | Stromberg William J | Director | P Open-market purchase | 1,000 | $61.69 | +$61.7K |
| 2026-05-07 | CULP H LAWRENCE JR | Director | P Open-market purchase | 80,805 | $61.88 | +$5.00M |
| 2026-05-01 | SACCARO JAMES | Chief Financial Officer | P Open-market purchase | 3,310 | $60.60 | +$200.6K |
| 2026-04-30 | Arduini Peter J | President and CEO | P Open-market purchase | 4,169 | $59.92 | +$249.8K |
| 2026-04-30 | Jimenez Frank R | GC & Corporate Secretary | P Open-market purchase | 1,750 | $60.45 | +$105.8K |
| 2026-03-17 | Lobo Kevin | Director | A Grant / award | 777 | — | +$0 |
| 2026-03-04 | Arduini Peter J | President and CEO | A Grant / award(deriv) | 129,140 | — | +$0 |
| 2026-03-04 | Arduini Peter J | President and CEO | A Grant / award | 49,120 | — | +$0 |
| 2026-03-04 | SACCARO JAMES | Chief Financial Officer | A Grant / award(deriv) | 32,797 | — | +$0 |
| 2026-03-04 | SACCARO JAMES | Chief Financial Officer | A Grant / award | 12,475 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-29upcoming | 1.03 | — | — |
| 2026-04-29 | 1.05 | 0.99 | -5.71% |
| 2026-02-04 | 1.40 | 1.44 | +2.99% |
| 2025-10-29 | 1.05 | 1.07 | +2.21% |
| 2025-07-30 | 0.92 | 1.06 | +15.41% |
| 2025-04-30 | 0.91 | 1.01 | +10.61% |
| 2025-02-13 | 1.26 | 1.45 | +14.77% |
| 2024-10-30 | 1.05 | 1.14 | +8.30% |
| 2024-07-31 | 0.98 | 1.00 | +2.37% |
| 2024-04-30 | 0.91 | 0.90 | -0.74% |
| 2024-02-06 | 1.07 | 1.18 | +9.82% |
| 2023-10-31 | 0.90 | 0.99 | +10.44% |
| 2023-07-25 | 0.87 | 0.92 | +5.85% |
| 2023-04-25 | 0.79 | 0.85 | +7.26% |
| 2023-01-30 | 1.06 | 1.21 | +14.15% |